Miami Herald

Back to normal? Not so fast, these COVID questions still need some answers

- BY LEANA S. WEN Leana S. Wen is a professor at George Washington University’s Milken Institute School of Public Health. The Washington Post

On March 11, 2020, the World Health Organizati­on officially designated the novel coronaviru­s as a pandemic. Two days later, then-President Trump declared a national emergency.

The third anniversar­y of those moments passed by over the past week without much fanfare. President Biden has already said the national emergency for COVID-19 will end this May, and most Americans have returned to their pre-pandemic lives.

Still, there are three remaining questions that scientists and policymake­rs must continue to address.

How can we protect the most vulnerable?

With COVID becoming endemic and no longer a daily considerat­ion for most people, the question of how to safeguard those still at high risk should be the top priority for health officials. This is in line with how we address virtually all other diseases, such as HIV and cancer. The priority should be the elderly, the immunocomp­romised and others who are not able to use existing treatments.

Globally, more than

80% of COVID deaths in 2020 and 2021 occurred among individual­s 60 and above. In the United States last year, almost 90% of COVID deaths were among people 65 and older. The antiviral Paxlovid is effective in reducing hospitaliz­ations and deaths in this age group, but many cannot take it because of certain medical conditions or because other medication­s they are taking interact poorly with the drug.

And now that the Food and Drug Administra­tion has withdrawn its authorizat­ion of the preventive antibody Evusheld, the immunocomp­romised are left with fewer options.

During the past three years, we have seen science and public health deliver remarkable successes with a record-setting vaccinatio­n campaign. We should marshal this same energy toward developing improved treatments and ensuring that these therapies reach people most at risk.

In the meantime, federal health agencies should allow second bivalent boosters for those who want them.

And entities frequented by vulnerable people, such as hospitals and senior centers, should keep their mask requiremen­ts in place.

How should we think about long COVID?

There is no question that long COVID is a serious and often life-changing ailment that affects many Americans. Yet it remains ill-defined and poorly understood.

Research, including a recent Nature paper, increasing­ly indicates that vaccinatio­n can reduce the incidence of long-haul symptoms. Another study, which is online but not yet peer-reviewed, suggests that taking Paxlovid can decrease the likelihood of developing long-term symptoms.

We need far more studies like these. One crucial area of inquiry is what happens with repeat infections, which will almost certainly become more common with COVID exposure going forward. We might come to expect some frequency of postCOVID symptoms, and the resulting disability, as a “new normal.” In that case, health resources must shift from avoiding the coronaviru­s to reducing and treating its worst consequenc­es — including long COVID.

How do we prepare for the twists and turns ahead?

COVIDhas not settled into a predictabl­e seasonal pattern. Variants currently circulatin­g are all offshoots of the milder and extremely transmissi­ble omicron strain, but it’s entirely possible that a more dangerous strain that can evade the protection of existing vaccines might emerge.

One silver lining from the past three years is the increased attention to disease surveillan­ce. Wastewater testing has proved successful at detecting COVID outbreaks early. These efforts should continue so that troublesom­e variants can be flagged. We also need to renew the urgency to develop vaccines that can cover a broader range of variants.

Then there’s the turmoil from the investigat­ions into COVID’s origins. Such inquiries should not delay necessary progress both to improve laboratory safety and to reduce transmissi­on of zoonotic infections, which are spread between people and animals. I hope political leaders approach these goals with scientific rigor rather than cherrypick­ed data points to fit predetermi­ned theories.

For more than three years, COVID has been inserted into the partisan culture wars, hindering our response and eroding trust in public health. COVID may no longer be a pandemic, but the impact of the virus itself is far from over.

There is much work to be done to protect those still at risk and prepare the United States for future infectious diseases.

 ?? IVAN DIAZ via Unsplash ?? It has been three years since then-President Trump declared COVID-19 a national emergency.
IVAN DIAZ via Unsplash It has been three years since then-President Trump declared COVID-19 a national emergency.
 ?? ??

Newspapers in English

Newspapers from United States